Home HOMEPAGE   Fri, 07/19/2024 GMT + 7
    Q & A   Site map Forum   Site map Sitemap   E-mali Contact   Vietnamese Vietnamese
Web Sites & Commerce News - Events
Web Sites & Commerce Introduction
Web Sites & Commerce Collaborative activities
Web Sites & Commerce Training
Web Sites & Commerce Specific research studies
Finance & Retail Publications
Published scientific research studies
Journal of Practical Medicine
Monographs of scientific research studies (2001-2006)
Web Sites & Commerce Mass organization activities
Web Sites & Commerce Legal documents
Web Sites & Commerce Statistical data
Web Sites & Commerce Work safety
Web Sites & Commerce Vietnam`s Physicians
Web Sites & Commerce Malariology
Web Sites & Commerce Helminthology
Web Sites & Commerce Other vector-borne diseases



Other links

Visiting users: 273
5 3 4 1 1 1 6 6
2 7 3
Part 2: New and effective antimalarial drugs in global malaria elimination strategies

The potential elimination of Plasmodium vivax malaria by relapse treatment: insights from a transmission model and surveillance data from NW India.

Roy M, Bouma MJ, Ionides EL, Dhiman RC, Pascual M.PLoS Negl Trop Dis. 2013;7(1):e1979. doi: 10.1371/journal.pntd.0001979.Epub 2013 Jan 10.PMID: 23326611Free PMC ArticleSimilar articlesSelect item 2838126194.

Challenges for achieving safe and effective radical cure of Plasmodium vivax: a round table discussion of the APMEN Vivax Working Group.

Thriemer K, Ley B, Bobogare A, Dysoley L, Alam MS, Pasaribu AP, Sattabongkot J, Jambert E, Domingo GJ, Commons R, Auburn S, Marfurt J, Devine A, Aktaruzzaman MM, Sohel N, Namgay R, Drukpa T, Sharma SN, Sarawati E, Samad I, Theodora M, Nambanya S, Ounekham S, Mudin RN, Da Thakur G, Makita LS, Deray R, Lee SE, Boaz L, Danansuriya MN, Mudiyanselage SD, Chinanonwait N, Kitchakarn S, Nausien J, Naket E, Duc TN, Do Manh H, Hong YS, Cheng Q, Richards JS, Kusriastuti R, Satyagraha A, Noviyanti R, Ding XC, Khan WA, Swe Phru C, Guoding Z, Qi G, Kaneko A, Miotto O, Nguitragool W, Roobsoong W, Battle K, Howes RE, Roca-Feltrer A, Duparc S, Bhowmick IP, Kenangalem E, Bibit JA, Barry A, Sintasath D, Abeyasinghe R, Sibley CH, McCarthy J, von Seidlein L, Baird JK, Price RN.

Malar J. 2017 Apr 5;16(1):141. doi: 10.1186/s12936-017-1784-1. Review.

PMID: 28381261Free PMC ArticleSimilar articlesSelect item 2379784395.

An LC-MS based study of the metabolic profile of primaquine, an 8-aminoquinoline antiparasitic drug, with an in vitro primary human hepatocyte culture model.

Jin X, Pybus BS, Marcsisin R, Logan T, Luong TL, Sousa J, Matlock N, Collazo V, Asher C, Carroll D, Olmeda R, Walker LA, Kozar MP, Melendez V.Eur J Drug Metab Pharmacokinet.2014 Jun;39(2):139-46.PMID: 23797843Similar articlesSelect item 3056527996.

Association between aripiprazole pharmacokinetics and CYP2D6 phenotypes: A systematic review and meta-analysis.

Zhang X, Xiang Q, Zhao X, Ma L, Cui Y.J Clin Pharm Ther. 2018 Dec 18. doi: 10.1111/jcpt.12780. [Epub ahead of print] Review.PMID: 30565279Similar articlesSelect item 2718885497.

Pre-clinical evaluation of CYP 2D6 dependent drug-drug interactions between primaquine and SSRI/SNRI antidepressants.

Jin X, Potter B, Luong TL, Nelson J, Vuong C, Potter C, Xie L, Zhang J, Zhang P, Sousa J, Li Q, Pybus BS, Kreishman-Deitrick M, Hickman M, Smith PL, Paris R, Reichard G, Marcsisin SR.Malar J. 2016 May 17;15(1):280. doi: 10.1186/s12936-016-1329-z.PMID: 27188854Free PMC ArticleSimilar articlesSelect item 2701647098.

Primaquine pharmacology in the context of CYP 2D6 pharmacogenomics: Current state of the art.

Marcsisin SR, Reichard G, Pybus BS.Pharmacol Ther. 2016 May;161:1-10. doi: 10.1016/j.pharmthera.2016.03.011. Epub 2016 Mar 22. Review.PMID: 27016470Free ArticleSimilar articlesSelect item 2589181299.

Killing the hypnozoite--drug discovery approaches to prevent relapse in Plasmodium vivax.

Campo B, Vandal O, Wesche DL, Burrows JN.Pathog Glob Health. 2015 May;109(3):107-22. doi: 10.1179/2047773215Y.0000000013. Epub 2015 Apr 18. Review.PMID: 25891812Free PMC ArticleSimilar articlesSelect item 30400893100.

Tafenoquine and primaquine do not exhibit clinical neurologic signs associated with central nervous system lesions in the same manner as earlier 8-aminoquinolines.

Berman J, Brown T, Dow G, Toovey S.Malar J. 2018 Nov 6;17(1):407. doi: 10.1186/s12936-018-2555-3. Review.PMID: 30400893Free PMC ArticleSimilar articles

The Use of In Vitro Data and Physiologically-Based Pharmacokinetic Modeling to Predict Drug Metabolite Exposure: Desipramine Exposure in Cytochrome P4502D6 Extensive and Poor Metabolizers Following Administration of Imipramine.

Nguyen HQ, Callegari E, Obach RS.Drug Metab Dispos. 2016 Oct;44(10):1569-78. doi: 10.1124/dmd.116.071639. Epub 2016 Jul 20.PMID: 27440861Similar articlesSelect item 25759576102.

Oral lipid-based nanoformulation of tafenoquine enhanced bioavailability and blood stage antimalarial efficacy and led to a reduction in human red blood cell loss in mice.

Melariri P, Kalombo L, Nkuna P, Dube A, Hayeshi R, Ogutu B, Gibhard L, deKock C, Smith P, Wiesner L, Swai H.Int J Nanomedicine. 2015 Feb 20;10:1493-503. doi: 10.2147/IJN.S76317. eCollection 2015.PMID: 25759576Free PMC ArticleSimilar articlesSelect item 29676238103.

Effect of CYP2D6 Poor Metabolizer Phenotype o­n Stereoselective Nebivolol Pharmacokinetics.

Vieira CP, Neves DV, Coelho EB, Lanchote VL.Drug Metab Lett. 2018;12(1):68-70. doi: 10.2174/1872312812666180420104945.PMID: 29676238Similar articlesSelect item 30058787104.

CYP2D6 basic genotyping as a potential tool to improve the antiemetic efficacy of o­ndansetron in prophylaxis of postoperative nausea and vomiting.

Niewi?ski PA, Wojciechowski R, ?liwi?ski M, Hurkacz ME, G?owacka K, Orzechowska-Juzwenko K, Wiela-Hoje?ska AK.Adv Clin Exp Med. 2018 Nov;27(11):1499-1503. doi: 10.17219/acem/69451.PMID: 30058787Free ArticleSimilar articlesSelect item 3542534105.

Pharmacokinetics of primaquine in patients with P. vivax malaria.

Bhatia SC, Saraph YS, Revankar SN, Doshi KJ, Bharucha ED, Desai ND, Vaidya AB, Subrahmanyam D, Gupta KC, Satoskar RS.Eur J Clin Pharmacol.1986;31(2):205-10. PMID: 3542534Similar articlesSelect item 28836792106.

Galactose-Anchored Gelatin Nanoparticles for Primaquine Delivery and Improved Pharmacokinetics: A Biodegradable and Safe Approach for Effective Antiplasmodial Activity against P. falciparum 3D7 and in Vivo Hepatocyte Targeting.

Kumar H, Gothwal A, Khan I, Nakhate KT, Alexander A, Ajazuddin, Singh V, Gupta U.Mol Pharm. 2017 Oct 2;14(10):3356-3369. doi: 10.1021/acs.molpharmaceut.7b00376. Epub 2017 Sep 11.PMID: 28836792Similar articlesSelect item 24913163107.

Scalable preparation and differential pharmacologic and toxicologic profiles of primaquine enantiomers.

Nanayakkara NP, Tekwani BL, Herath HM, Sahu R, Gettayacamin M, Tungtaeng A, van Gessel Y, Baresel P, Wickham KS, Bartlett MS, Fronczek FR, Melendez V, Ohrt C, Reichard GA, McChesney JD, Rochford R, Walker LA.Antimicrob Agents Chemother. 2014 Aug;58(8):4737-44. doi: 10.1128/AAC.02674-13. Epub 2014 Jun 9.PMID: 24913163Free PMC ArticleSimilar articlesSelect item 29510711108.

The ethics of using placebo in randomised controlled trials: a case study of a Plasmodium vivax antirelapse trial.

Cheah PY, Steinkamp N, von Seidlein L, Price RN.BMC Med Ethics. 2018 Mar 6;19(1):19. doi: 10.1186/s12910-018-0259-4.PMID: 29510711Free PMC ArticleSimilar articlesSelect item 10615272109.

The evolution of tafenoquine--antimalarial for a new millennium?

Peters W.J R Soc Med. 1999 Jul;92(7):345-52. Review. No abstract available. PMID: 10615272Free PMC ArticleSimilar articlesSelect item 27721533110.

Evaluation of pharmacokinetics of single-dose chloroquine in malnourished children with malaria- a comparative study with normally nourished children.

Kadam PP, Gogtay NJ, Karande S, Shah V, Thatte UM.Indian J Pharmacol. 2016 Sep-Oct;48(5):498-502.PMID: 27721533Free PMC ArticleSimilar articlesSelect item 29869298111.

Application of the Stable Isotope Label Approach in Clinical Development-Supporting Dissolution Specifications for a Commercial Tablet Product with Tafenoquine, a Long Half-life Compound.

Goyal N, Mohamed K, Rolfe K, Sahota S, Ernest T, Duparc S, Taylor M, Casillas L, Koh GCKW.AAPS J. 2018 Jun 4;20(4):74. doi: 10.1208/s12248-018-0234-5.PMID: 29869298Similar articlesSelect item 22399238112.

The dopaminergic stabilizer pridopidine is to a major extent N-depropylated by CYP2D6 in humans.

Helldn A, Panagiotidis G, Johansson P, Waters N, Waters S, Tedroff J, Bertilsson L.Eur J Clin Pharmacol. 2012 Sep;68(9):1281-6. doi: 10.1007/s00228-012-1248-z. Epub 2012 Mar 8.PMID: 22399238Similar articlesSelect item 29317838113.

Primaquine double dose for 7 days is inferior to single-dose treatment for 14 days in preventingPlasmodium vivaxrecurrent episodes in Suriname.

Mac Donald-Ottevanger MS, Adhin MR, Jitan JK, Bretas G, Vreden SG.Infect Drug Resist. 2017 Dec 20;11:3-8. doi: 10.2147/IDR.S135897. eCollection 2018.PMID: 29317838Free PMC ArticleSimilar articlesSelect item 27093859114.

Differential kinetic profiles and metabolism of primaquine enantiomers by human hepatocytes.

Fasinu PS, Avula B, Tekwani BL, Nanayakkara NP, Wang YH, Bandara Herath HM, McChesney JD, Reichard GA, Marcsisin SR, Elsohly MA, Khan SI, Khan IA, Walker LA.Malar J. 2016 Apr 19;15:224. doi: 10.1186/s12936-016-1270-1.PMID: 27093859Free PMC ArticleSimilar articlesSelect item 13793053115.

Mitigation of the haemolytic effect of primaquine and enhancement of its action against exoerythrocytic forms of the Chesson strain of Piasmodium vivax by intermittent regimens of drug administration: a preliminary report.

ALVING AS, JOHNSON CF, TARLOV AR, BREWER GJ, KELLERMEYER RW, CARSON PE.Bull World Health Organ. 1960;22:621-31.PMID: 13793053Free PMC ArticleSimilar articlesSelect item 22144436116.

Review: Improving the therapeutic index of 8-aminoquinolines by the use of drug combinations: review of the literature and proposal for future investigations.

Myint HY, Berman J, Walker L, Pybus B, Melendez V, Baird JK, Ohrt C.Am J Trop Med Hyg. 2011 Dec;85(6):1010-4. doi: 10.4269/ajtmh.2011.11-0498. Review.PMID: 22144436Free PMC ArticleSimilar articlesSelect item 25295216117.

Antirelapse Efficacy of Various Primaquine Regimens for Plasmodium vivax.

Rajgor DD, Gogtay NJ, Kadam VS, Kocharekar MM, Parulekar MS, Dalvi SS, Vaidya AB, Kshirsagar NA.Malar Res Treat. 2014;2014:347018. doi: 10.1155/2014/347018. Epub 2014 Sep 10.PMID: 25295216Free PMC ArticleSimilar articlesSelect item 24360370118.

Single-dose radical cure of Plasmodium vivax: a step closer.

Price RN, Nosten F.Lancet. 2014 Mar 22;383(9922):1020-1. doi: 10.1016/S0140-6736(13)62672-0. Epub 2013 Dec 19. No abstract available. PMID: 24360370Free PMC ArticleSimilar articlesSelect item 30706164119.

Effects of MAO-A and CYP450 o­n primaquine metabolism in healthy volunteers.

Ariffin NM, Islahudin F, Kumolosasi E, Makmor-Bakry M.Parasitol Res. 2019 Jan 31. doi: 10.1007/s00436-019-06210-3. [Epub ahead of print]PMID: 30706164Similar articlesSelect item 29713556120.

Relapsing Malaria: A Case Report of Primaquine Resistance.

Dijanic C, Nickerson J, Shakya S, Dijanic A, Fabbri M.Case Rep Infect Dis. 2018 Mar 11;2018:9720823. doi: 10.1155/2018/9720823. eCollection 2018.PMID: 29713556Free PMC ArticleSimilar articles

Chloroquine-Primaquine Therapeutic Efficacy, Safety, and Plasma Levels in Patients with UncomplicatedPlasmodium vivaxMalaria in a Colombian Pacific Region.

Mesa-Echeverry E, Niebles-Bolvar M, Tobn-Castao A.Am J Trop Med Hyg. 2019 Jan;100(1):72-77. doi: 10.4269/ajtmh.18-0655.PMID: 30457097Similar articlesSelect item 14804087122.

Primaquine, SN 13272, a new curative agent in vivax malaria; a preliminary report.

Edgcomb jh, arnold j, yount eh jr, alving as, eichelberger l, jeffery gm, eyles d, young md.J Natl Malar Soc. 1950 Dec;9(4):285-92.No abstract available. PMID: 14804087Similar articlesSelect item 25385861123.

Performance of BinaxNOW G6PD deficiency point-of-care diagnostic in P. vivax-infected subjects.

Osorio L, Carter N, Arthur P, Bancone G, Gopalan S, Gupta SK, Noedl H, Kochar SK, Kochar DK, Krudsood S, Lacerda MV, Llanos-Cuentas A, Rueangweerayut R, Srinivasan R, Treiber M, Mhrle JJ, Green J.

Am J Trop Med Hyg. 2015 Jan;92(1):22-7. doi: 10.4269/ajtmh.14-0298. Epub 2014 Nov 10.

PMID: 25385861Free PMC ArticleSimilar articlesSelect item 28070879124.

A Review of Pharmacogenetics of Antimalarials and Associated Clinical Implications.

Elewa H, Wilby KJ.Eur J Drug Metab Pharmacokinet. 2017 Oct;42(5):745-756. doi: 10.1007/s13318-016-0399-1. Review.PMID: 28070879Similar articlesSelect item 30229442125.

Tafenoquine: First Global Approval.

Frampton JE.Drugs. 2018 Sep;78(14):1517-1523. doi: 10.1007/s40265-018-0979-2.PMID: 30229442Similar articlesSelect item 30380095126.

Tafenoquine for travelers' malaria: evidence, rationale and recommendations.

Baird JK.J Travel Med. 2018 Jan 1;25(1). doi: 10.1093/jtm/tay110.PMID: 30380095Free PMC ArticleSimilar articlesSelect item 28350251127.

Impact of CYP2D6 genotype o­n amitriptyline efficacy for the treatment of diabetic peripheral neuropathy: a pilot study.

Chaudhry M, Alessandrini M, Rademan J, Dodgen TM, Steffens FE, van Zyl DG, Gaedigk A, Pepper MS.Pharmacogenomics. 2017 Apr;18(5):433-443. doi: 10.2217/pgs-2016-0185. Epub 2017 Mar 28.PMID: 28350251Free ArticleSimilar articlesSelect item 27072954128.

Minimization of CYP2D6 Polymorphic Differences and Improved Bioavailability via Transdermal Administration: Latrepirdine Example.

Chew ML, Mordenti J, Yeoh T, Ranade G, Qiu R, Fang J, Liang Y, Corrigan B.Pharm Res. 2016 Aug;33(8):1873-80. doi: 10.1007/s11095-016-1922-4. Epub 2016 Apr 12.PMID: 27072954Similar articlesSelect item 30670877129.

CYP2D6-guided opioid therapy improves pain control in CYP2D6 intermediate and poor metabolizers: a pragmatic clinical trial.

Smith DM, Weitzel KW, Elsey AR, Langaee T, Gong Y, Wake DT, Duong BQ, Hagen M, Harle CA, Mercado E, Nagoshi Y, Newsom K, Wright A, Rosenberg EI, Starostik P, Clare-Salzler MJ, Schmidt SO, Fillingim RB, Johnson JA, Cavallari LH.Genet Med. 2019 Jan 23. doi: 10.1038/s41436-018-0431-8. [Epub ahead of print]. PMID: 30670877Similar articlesSelect item 14945979130.

Cure of Korean vivax malaria with pamaquine and primaquine.

GARRISON PL, HANKEY DD, COKER WG, DONOVAN WN, JASTREMSKI B, COATNEY GR, ALVING AS, JONES R Jr.J Am Med Assoc. 1952 Aug 23;149(17):1562-3. No abstract available. PMID: 14945979Similar articlesSelect item 26528073131.

Phenotypic differences in nebivolol metabolism and bioavailability in healthy volunteers.

Briciu C, Neag M, Muntean D, Bocsan C, Buzoianu A, Antonescu O, Gheldiu AM, Achim M, Popa A, Vlase L.Clujul Med. 2015;88(2):208-13. doi: 10.15386/cjmed-395. Epub 2015 Apr 15.PMID: 26528073Free PMC ArticleSimilar articlesSelect item 21970596132.

Pharmacogenetic testing affects choice of therapy among women considering tamoxifen treatment.

Lorizio W, Rugo H, Beattie MS, Tchu S, Melese T, Melisko M, Wu AH, Lawrence HJ, Nikoloff M, Ziv E. Genome Med. 2011 Oct 4;3(10):64. doi: 10.1186/gm280.PMID: 21970596Free PMC ArticleSimilar articlesSelect item 14419205133.

Use of quinocide in treatment and prophylaxis of vivax malaria.

LYSENKO AY.Bull World Health Organ. 1960;22:641-62.PMID: 14419205Free PMC ArticleSimilar articlesSelect item 27223244134.

Methemoglobinemia Hemotoxicity of Some Antimalarial 8-Aminoquinoline Analogues and Their Hydroxylated Derivatives: Density Functional Theory Computation of Ionization Potentials.

Ding Y, Liu H, Tekwani BL, Nanayakkara NP, Khan IA, Walker LA, Doerksen RJ.

Chem Res Toxicol. 2016 Jul 18;29(7):1132-41. doi: 10.1021/acs.chemrestox.6b00063. Epub 2016 Jul 1.

PMID: 27223244Similar articlesSelect item 30650321135.

Tafenoquine - A Radical Improvement?

White NJ.

N Engl J Med. 2019 Jan 17;380(3):285-286. doi: 10.1056/NEJMe1816383. No abstract available.

PMID: 30650321Similar articlesSelect item 30485867136.

The Associations Between CYP2D6 Metabolizer Status and Pharmacokinetics and Clinical Outcomes of Venlafaxine: A Systematic Review and Meta-Analysis.

Lin XQ, Wang P, Cai WK, Xu GL, Yang M, Zhou MD, Sun M, He F, He GH.

Pharmacopsychiatry. 2018 Nov 28. doi: 10.1055/a-0792-1340. [Epub ahead of print]

PMID: 30485867Similar articlesSelect item 20343588137.

Pentaquine (SN-13,276) a new antimalarial effective in reducing the relapse rate of vivax malaria.


Proc Annu Meet Cent Soc Clin Res U S. 1946 Nov 1-2;19:83. No abstract available.

PMID: 20343588Similar articlesSelect item 21064280138.

Pamaquin; curative antimalarial activity in vivax malaria.


Fed Proc. 1946;5(1 Pt 2):165. No abstract available.

PMID: 21064280Similar articlesSelect item 23965782139.

Pharmacometric Analyses to Support Early Development Decisions for LY2878735: A Novel Serotonin Norepinephrine Reuptake Inhibitor.

Raddad E, Melhem MR, Sloan-Lancaster JS, Miller JW, Van Wart SA, Rubino CM.

CPT Pharmacometrics Syst Pharmacol. 2013 Aug 21;2:e66. doi: 10.1038/psp.2013.43.

PMID: 23965782Free PMC ArticleSimilar articlesSelect item 18872928140.

Study of pentaquine and isopentaquine, therapeutic agents effective in reducing relapse rate in vivax malaria.


Abstr Int Congr Trop Med Malar. 1948;56(4th Congr):58. No abstract available.

PMID: 18872928Similar articles

Combined quinine-plasmochin treatment of vivax malaria; effect of relapse rate.

MOST H, KANE CA, et al.

Am J Med Sci. 1946 Nov;212(5):550-60. No abstract available.

PMID: 20273918Similar articlesSelect item 29301387142.

Pharmacogenetics of Vascular Risk Factors in Alzheimer's Disease.

Cacabelos R, Meyyazhagan A, Carril JC, Cacabelos P, Teijido .

J Pers Med. 2018 Jan 3;8(1). pii: E3. doi: 10.3390/jpm8010003. Review.

PMID: 29301387Free PMC ArticleSimilar articlesSelect item 18905562143.

Combined quinine-plasmochin and quinine-pentaquine treatment of relapsing vivax malaria.


South Med J. 1948 Apr;41(4):338-41. No abstract available.

PMID: 18905562Similar articlesSelect item 14790523144.

Radical cure of relapsing vivax malaria with pentaquine-quinine; a controlled study.


Ann Intern Med. 1950 Dec;33(6):1413-22.No abstract available.

PMID: 14790523Similar articlesSelect item 18121216145.

Studies in human malaria; the therapeutic action of pamaquine against St. Elizabeth strain vivax malaria.


Am J Hyg. 1949 May;49(3):367-73. No abstract available.

PMID: 18121216Similar articlesSelect item 18860176146.

Pentaquine (SN-13,276) a therapeutic agent effective in reducing the relapse rate in vivax malaria.


J Clin Invest. 1948 May;27(3 Pt1):25-33. No abstract available.

PMID: 18860176Similar articlesSelect item 18860470147.

Evaluation of pentaquine as a cure of relapsing vivax malaria; a controlled study of 95 cases.


Bull N Y Acad Med. 1948 Jun;24(6):395. No abstract available.

PMID: 18860470Free PMC ArticleSimilar articlesSelect item 14795202148.

Studies in human malaria. XXVII. Observations o­n the use of pentaquine in the prevention and treatment of Chesson strain vivax malaria.


J Natl Malar Soc. 1950 Sep;9(3):222-33. No abstract available.

PMID: 14795202Similar articlesSelect item 18123173149.

Cure of chronic vivax malaria with pentaquine.


J Am Med Assoc. 1949 Feb 12;139(7):437-9. No abstract available.

PMID: 18123173Similar articlesSelect item 18152607150.

Cure of chronic vivax malaria with pentaquine and status of immunity thereafter.


Proc Inst Med Chic. 1949 Jun 15;17(15):357. No abstract available.

PMID: 18152607Similar articlesSelect item 30137454151.

Tafenoquine receives regulatory approval in USA for prophylaxis of malaria and radical cure of Plasmodium vivax.

Tan KR, Hwang J.

J Travel Med. 2018 Jan 1;25(1). doi: 10.1093/jtm/tay071. No abstract available.

PMID: 30137454Similar articlesSelect item 24266826152.

On naturalistic pharmacogenetic studies: reply from the authors.

Seip RL, Goethe JW, Schwartz HI, Ruao G.

Biomark Med. 2013 Dec;7(6):917-8. doi: 10.2217/bmm.13.110. No abstract available.

PMID: 24266826Free ArticleSimilar articlesSelect item 29389962153.

Correction: Variation in Human Cytochrome P-450 Drug-Metabolism Genes: A Gateway to the Understanding of Plasmodium vivax Relapses.

Silvino ACR, Costa GL, Arajo FCF, Ascher DB, Pires DEV, Fontes CJF, Carvalho LH, Brito CFA, Sousa TN.

PLoS o­ne. 2018 Feb 1;13(2):e0192534. doi: 10.1371/journal.pone.0192534. eCollection 2018.

PMID: 29389962Free PMC ArticleSimilar articlesSelect item 28729716154.

Pharmacogenetic comparison of CYP2D6 predictive and measured phenotypes in a South African cohort.

Dodgen TM, De J Labuschagne C, van Schalkwyk A, Steffens FE, Gaedigk A, Cromarty AD, Alessandrini M, Pepper MS.

Pharmacogenomics J. 2017 Jul;17(4):393. doi: 10.1038/tpj.2017.20.

PMID: 28729716Similar articles

Tafenoquine for travelers' malaria: evidence, rationale and recommendations.

Baird JK.

J Travel Med. 2018 Jan 1;25(1). doi: 10.1093/jtm/tay110.

PMID: 30380095Free PMC ArticleSimilar articlesSelect item 302294422.

Tafenoquine: First Global Approval.

Frampton JE.

Drugs. 2018 Sep;78(14):1517-1523. doi: 10.1007/s40265-018-0979-2.

PMID: 30229442Similar articlesSelect item 288839773.

Management ofPlasmodium vivaxrisk and illness in travelers.

Baird JK.

Trop Dis Travel Med Vaccines. 2017 Mar 28;3:7. doi: 10.1186/s40794-017-0049-x. eCollection 2017.

PMID: 28883977Free PMC ArticleSimilar articlesSelect item 296771994.

Implications of current therapeutic restrictions for primaquine and tafenoquine in the radical cure of vivax malaria.

Watson J, Taylor WRJ, Bancone G, Chu CS, Jittamala P, White NJ.

PLoS Negl Trop Dis. 2018 Apr 20;12(4):e0006440. doi: 10.1371/journal.pntd.0006440. eCollection 2018 Apr.

PMID: 29677199Free PMC ArticleSimilar articlesSelect item 243603695.

Tafenoquine plus chloroquine for the treatment and relapse prevention of Plasmodium vivax malaria (DETECTIVE): a multicentre, double-blind, randomised, phase 2b dose-selection study.

Llanos-Cuentas A, Lacerda MV, Rueangweerayut R, Krudsood S, Gupta SK, Kochar SK, Arthur P, Chuenchom N, Mhrle JJ, Duparc S, Ugwuegbulam C, Kleim JP, Carter N, Green JA, Kellam L.

Lancet. 2014 Mar 22;383(9922):1049-58. doi: 10.1016/S0140-6736(13)62568-4. Epub 2013 Dec 19.

PMID: 24360369Similar articlesSelect item 275288006.

Tafenoquine and its potential in the treatment and relapse prevention of Plasmodium vivax malaria: the evidence to date.

Ebstie YA, Abay SM, Tadesse WT, Ejigu DA.

Drug Des Devel Ther. 2016 Jul 26;10:2387-99. doi: 10.2147/DDDT.S61443. eCollection 2016. Review.

PMID: 27528800Free PMC ArticleSimilar articlesSelect item 154868317.

Randomized trial of 3-dose regimens of tafenoquine (WR238605) versus low-dose primaquine for preventing Plasmodium vivax malaria relapse.

Walsh DS, Wilairatana P, Tang DB, Heppner DG Jr, Brewer TG, Krudsood S, Silachamroon U, Phumratanaprapin W, Siriyanonda D, Looareesuwan S.

Clin Infect Dis. 2004 Oct 15;39(8):1095-103. Epub 2004 Sep 24.

PMID: 15486831Similar articlesSelect item 304008938.

Tafenoquine and primaquine do not exhibit clinical neurologic signs associated with central nervous system lesions in the same manner as earlier 8-aminoquinolines.

Berman J, Brown T, Dow G, Toovey S.

Malar J. 2018 Nov 6;17(1):407. doi: 10.1186/s12936-018-2555-3. Review.

PMID: 30400893Free PMC ArticleSimilar articlesSelect item 291210619.

A randomized, double-blind, active-control trial to evaluate the efficacy and safety of a three day course of tafenoquine monotherapy for the treatment of Plasmodium vivax malaria.

Fukuda MM, Krudsood S, Mohamed K, Green JA, Warrasak S, Noedl H, Euswas A, Ittiverakul M, Buathong N, Sriwichai S, Miller RS, Ohrt C.

PLoS o­ne. 2017 Nov 9;12(11):e0187376. doi: 10.1371/journal.pone.0187376. eCollection 2017.

PMID: 29121061Free PMC ArticleSimilar articlesSelect item 1854128010.

The efficacy and tolerability of three different regimens of tafenoquine versus primaquine for post-exposure prophylaxis of Plasmodium vivax malaria in the Southwest Pacific.

Elmes NJ, Nasveld PE, Kitchener SJ, Kocisko DA, Edstein MD.

Trans R Soc Trop Med Hyg. 2008 Nov;102(11):1095-101. doi: 10.1016/j.trstmh.2008.04.024.Epub 2008 Jun 9.

PMID: 18541280Similar articlesSelect item 2841734611.

[Role of primaquine in malaria control and elimination in French-speaking Africa].

Briolant S, Pradines B, Basco LK.

Bull Soc Pathol Exot. 2017 Aug;110(3):198-206. doi: 10.1007/s13149-017-0556-z. Epub 2017 Apr 17. Review. French.

PMID: 28417346Similar articlesSelect item 2688008812.

UK malaria treatment guidelines 2016.

Lalloo DG, Shingadia D, Bell DJ, Beeching NJ, Whitty CJM, Chiodini PL; PHE Advisory Committee o­n Malaria Prevention in UK Travellers.

J Infect. 2016 Jun;72(6):635-649. doi: 10.1016/j.jinf.2016.02.001.Epub 2016 Feb 12.

PMID: 26880088Similar articlesSelect item 2180140013.

Radical curative efficacy of tafenoquine combination regimens in Plasmodium cynomolgi-infected Rhesus monkeys (Macaca mulatta).

Dow GS, Gettayacamin M, Hansukjariya P, Imerbsin R, Komcharoen S, Sattabongkot J, Kyle D, Milhous W, Cozens S, Kenworthy D, Miller A, Veazey J, Ohrt C.

Malar J. 2011 Jul 29;10:212. doi: 10.1186/1475-2875-10-212.

PMID: 21801400Free PMC ArticleSimilar articlesSelect item 2450267914.

A retrospective analysis of the protective efficacy of tafenoquine and mefloquine as prophylactic anti-malarials in non-immune individuals during deployment to a malaria-endemic area.

Dow GS, McCarthy WF, Reid M, Smith B, Tang D, Shanks GD.

Malar J. 2014 Feb 6;13:49. doi: 10.1186/1475-2875-13-49.

PMID: 24502679Free PMC ArticleSimilar articlesSelect item 2345420415.

Suppressive chemoprophylaxis invites avoidable risk of serious illness caused by Plasmodium vivax malaria.

Baird JK.

Travel Med Infect Dis. 2013 Jan-Feb;11(1):60-5. doi: 10.1016/j.tmaid.2013.01.002. Epub 2013 Feb 28.

PMID: 23454204Free PMC ArticleSimilar articlesSelect item 2665410116.

Randomized trial of primaquine hypnozoitocidal efficacy when administered with artemisinin-combined blood schizontocides for radical cure of Plasmodium vivax in Indonesia.

Nelwan EJ, Ekawati LL, Tjahjono B, Setiabudy R, Sutanto I, Chand K, Ekasari T, Djoko D, Basri H, Taylor WR, Duparc S, Subekti D, Elyazar I, Noviyanti R, Sudoyo H, Baird JK.

BMC Med. 2015 Dec 11;13:294. doi: 10.1186/s12916-015-0535-9.

PMID: 26654101Free PMC ArticleSimilar articlesSelect item 2548242717.

Optimal primaquine use for radical cure of Plasmodium vivax and Plasmodium ovale malaria in Japanese travelers--A retrospective analysis.

Shimizu S, Kikuchi T, Koga M, Kato Y, Matsuoka H, Maruyama H, Kimura M; Research Group o­n Chemotherapy of Tropical Diseases.

Travel Med Infect Dis. 2015 May-Jun;13(3):235-40. doi: 10.1016/j.tmaid.2014.11.005. Epub 2014 Nov 20.

PMID: 25482427Similar articlesSelect item 2348437418.

[Clinical experience of primaquine use for treatment of vivax and ovale malaria in Japanese travelers].

Kobayashi T, Kato Y, Yamauchi Y, Ujiie M, Takeshita N, Mizuno Y, Kanagawa S, Kano S, Ohmagari N.

Kansenshogaku Zasshi. 2013 Jan;87(1):22-6. Japanese.

PMID: 23484374Similar articlesSelect item 2150892119.

Malaria surveillance--United States, 2009.

Mali S, Tan KR, Arguin PM; Division of Parasitic Diseases and Malaria, Center for Global Health; Centers for Disease Control and Prevention.

MMWR Surveill Summ. 2011 Apr 22;60(3):1-15.

PMID: 21508921Free ArticleSimilar articles

Select item 2874977320.

Hemolytic Potential of Tafenoquine in Female Volunteers Heterozygous for Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency (G6PD MahidolVariant) versus G6PD-Normal Volunteers.

Rueangweerayut R, Bancone G, Harrell EJ, Beelen AP, Kongpatanakul S, Mhrle JJ, Rousell V, Mohamed K, Qureshi A, Narayan S, Yubon N, Miller A, Nosten FH, Luzzatto L, Duparc S, Kleim JP, Green JA.

Am J Trop Med Hyg. 2017 Sep;97(3):702-711. doi: 10.4269/ajtmh.16-0779. Epub 2017 Jul 27.

PMID: 28749773Free PMC ArticleSimilar articles

Malaria Surveillance - United States, 2015.

Mace KE, Arguin PM, Tan KR.

MMWR Surveill Summ. 2018 May 4;67(7):1-28. doi: 10.15585/mmwr.ss6707a1.

PMID: 29723168Free PMC ArticleSimilar articlesSelect item 1746174222.

Tafenoquine: a promising new antimalarial agent.

Crockett M, Kain KC.

Expert Opin Investig Drugs.2007 May;16(5):705-15. Review.

PMID: 17461742Similar articlesSelect item 1271110123.

Blood schizontocidal activity of WR 238605 (Tafenoquine) against Plasmodium cynomolgi and Plasmodium fragile infections in rhesus monkeys.

Puri SK, Dutta GP.

Acta Trop. 2003 Apr;86(1):35-40.

PMID: 12711101Similar articlesSelect item 2665288724.

Point-of-care G6PD diagnostics for Plasmodium vivax malaria is a clinical and public health urgency.

Baird JK.

BMC Med. 2015 Dec 14;13:296. doi: 10.1186/s12916-015-0531-0.

PMID: 26652887Free PMC ArticleSimilar articlesSelect item 2967251625.

Use of primaquine and glucose-6-phosphate dehydrogenase deficiency testing: Divergent policies and practices in malaria endemic countries.

Recht J, Ashley EA, White NJ.

PLoS Negl Trop Dis. 2018 Apr 19;12(4):e0006230. doi: 10.1371/journal.pntd.0006230. eCollection 2018 Apr. Review.

PMID: 29672516Free PMC ArticleSimilar articlesSelect item 1554122326.

Imported Plasmodium vivax malaria: demographic and clinical features in nonimmune travelers.

Elliott JH, O'Brien D, Leder K, Kitchener S, Schwartz E, Weld L, Brown GV, Kain KC, Torresi J; GeoSentinel Surveillance Network.

J Travel Med. 2004 Jul-Aug;11(4):213-7.

PMID: 15541223Free ArticleSimilar articlesSelect item 2707730927.

Primaquine treatment and relapse in Plasmodium vivax malaria.

Rishikesh K, Saravu K.

Pathog Glob Health. 2016;110(1):1-8. doi: 10.1080/20477724.2015.1133033. Epub 2016 Feb 18. Review.

PMID: 27077309Free PMC ArticleSimilar articlesSelect item 2753013928.

Management of relapsing Plasmodium vivax malaria.

Chu CS, White NJ.

Expert Rev Anti Infect Ther. 2016 Oct;14(10):885-900. doi: 10.1080/14787210.2016.1220304. Epub 2016 Aug 31. Review.

PMID: 27530139Free PMC ArticleSimilar articlesSelect item 1143890829.

Malaria chemoprophylaxis in the age of drug resistance. II. Drugs that may be available in the future.

Shanks GD, Kain KC, Keystone JS.

Clin Infect Dis. 2001 Aug 1;33(3):381-5. Epub 2001 Jul 5. Review.

PMID: 11438908Similar articlesSelect item 1570155430.

New strategies for the prevention of malaria in travelers.

Chen LH, Keystone JS.

Infect Dis Clin North Am. 2005 Mar;19(1):185-210. Review.

PMID: 15701554Similar articlesSelect item 1158465731.

Malaria prophylaxis/radical cure: recent experiences of the Australian Defence Force.

Edstein MD, Walsh DS, Eamsila C, Sasiprapha T, Nasveld PE, Kitchener S, Rieckmann KH.

Med Trop (Mars). 2001;61(1):56-8. Review.

PMID: 11584657Similar articlesSelect item 2237796232.

Malaria surveillance--United States, 2010.

Mali S, Kachur SP, Arguin PM; Division of Parasitic Diseases and Malaria, Center for Global Health; Centers for Disease Control and Prevention (CDC).

MMWR Surveill Summ. 2012 Mar 2;61(2):1-17.

PMID: 22377962Free ArticleSimilar articlesSelect item 2710904033.

Therapeutic failure of primaquine and need for new medicines in radical cure of Plasmodium vivax.

Thomas D, Tazerouni H, Sundararaj KG, Cooper JC.

Acta Trop. 2016 Aug;160:35-8. doi: 10.1016/j.actatropica.2016.04.009.Epub 2016 Apr 21. Review.

PMID: 27109040Similar articlesSelect item 2854212334.

Malaria Surveillance - United States, 2014.

Mace KE, Arguin PM.

MMWR Surveill Summ. 2017 May 26;66(12):1-24. doi: 10.15585/mmwr.ss6612a1.

PMID: 28542123Free PMC ArticleSimilar articlesSelect item 1999593335.

Randomized, double-blind study of the safety, tolerability, and efficacy of tafenoquine versus mefloquine for malaria prophylaxis in nonimmune subjects.

Nasveld PE, Edstein MD, Reid M, Brennan L, Harris IE, Kitchener SJ, Leggat PA, Pickford P, Kerr C, Ohrt C, Prescott W; Tafenoquine Study Team.

Antimicrob Agents Chemother. 2010 Feb;54(2):792-8. doi: 10.1128/AAC.00354-09. Epub 2009 Dec 7.

PMID: 19995933Free PMC ArticleSimilar articlesSelect item 1736087336.

Tafenoquine for the treatment of recurrent Plasmodium vivax malaria.

Kitchener S, Nasveld P, Edstein MD.

Am J Trop Med Hyg. 2007 Mar;76(3):494-6.

PMID: 17360873Similar articlesSelect item 2319948937.

Diagnosis and treatment of Plasmodium vivax malaria.

Baird KJ, Maguire JD, Price RN.

Adv Parasitol. 2012;80:203-70. doi: 10.1016/B978-0-12-397900-1.00004-9. Review.

PMID: 23199489Similar articlesSelect item 2885706438.

Implementation of G6PD testing and primaquine forP. vivaxradical cure: Operational perspectives from Thailand and Cambodia.

Kitchakarn S, Lek D, Thol S, Hok C, Saejeng A, Huy R, Chinanonwait N, Thimasarn K, Wongsrichanalai C.

WHO South East Asia J Public Health. 2017 Sep;6(2):60-68.

PMID: 28857064Free ArticleSimilar articlesSelect item 2549560739.

The clinical and public health problem of relapse despite primaquine therapy: case review of repeated relapses of Plasmodium vivax acquired in Papua New Guinea.

Ingram RJ, Crenna-Darusallam C, Soebianto S, Noviyanti R, Baird JK.

Malar J. 2014 Dec 12;13:488. doi: 10.1186/1475-2875-13-488.

PMID: 25495607Free PMC ArticleSimilar articlesSelect item 2547416040.

Malaria surveillance--United States, 2012.

Cullen KA, Arguin PM; Centers for Disease Control and Prevention (CDC).

MMWR Surveill Summ. 2014 Dec 5;63(12):1-22.

PMID: 25474160Free ArticleSimilar articles

Tolerability and safety of weekly primaquine against relapse of Plasmodium vivax in Cambodians with glucose-6-phosphate dehydrogenase deficiency.

Kheng S, Muth S, Taylor WR, Tops N, Kosal K, Sothea K, Souy P, Kim S, Char CM, Vanna C, Ly P, Ringwald P, Khieu V, Kerleguer A, Tor P, Baird JK, Bjorge S, Menard D, Christophel E.

BMC Med. 2015 Aug 25;13:203. doi: 10.1186/s12916-015-0441-1.

PMID: 26303162Free PMC ArticleSimilar articlesSelect item 1709077042.

Prevention of malaria in long-term travelers.

Chen LH, Wilson ME, Schlagenhauf P.

JAMA. 2006 Nov 8;296(18):2234-44. Review.

PMID: 17090770Similar articlesSelect item 1696891343.

Primaquine: report from CDC expert meeting o­n malaria chemoprophylaxis I.

Hill DR, Baird JK, Parise ME, Lewis LS, Ryan ET, Magill AJ.

Am J Trop Med Hyg. 2006 Sep;75(3):402-15.

PMID: 16968913Similar articlesSelect item 2693813944.

Malaria Surveillance - United States, 2013.

Cullen KA, Mace KE, Arguin PM; Centers for Disease Control and Prevention (CDC).

MMWR Surveill Summ. 2016 Mar 4;65(2):1-22. doi: 10.15585/mmwr.ss6502a1.

PMID: 26938139Similar articlesSelect item 1537843845.

Efficacy of monthly tafenoquine for prophylaxis of Plasmodium vivax and multidrug-resistant P. falciparum malaria.

Walsh DS, Eamsila C, Sasiprapha T, Sangkharomya S, Khaewsathien P, Supakalin P, Tang DB, Jarasrumgsichol P, Cherdchu C, Edstein MD, Rieckmann KH, Brewer TG.

J Infect Dis. 2004 Oct 15;190(8):1456-63. Epub 2004 Sep 20.

PMID: 15378438Similar articlesSelect item 1755707446.

Malaria surveillance - United States, 2005.

Thwing J, Skarbinski J, Newman RD, Barber AM, Mali S, Roberts JM, Slutsker L, Arguin PM; Centers for Disease Control and Prevention.

MMWR Surveill Summ. 2007 Jun 8;56(6):23-40.

PMID:17557074Free ArticleS imilar articlesSelect item 1032335947.

Malaria prevention in travelers.

Juckett G.

Am Fam Physician. 1999 May 1;59(9):2523-30, 2535-6. Review. Erratum in: Am Fam Physician 2000 Jan 1;61(1):50, 52.

PMID: 10323359Free ArticleSimilar articlesSelect item 1088535648.

Malaria chemoprophylaxis with tafenoquine: a randomised study.

Lell B, Faucher JF, Missinou MA, Borrmann S, Dangelmaier O, Horton J, Kremsner PG.

Lancet. 2000 Jun 10;355(9220):2041-5.

PMID: 10885356Similar articlesSelect item 2325443749.

Randomized, open-label trial of primaquine against vivax malaria relapse in Indonesia.

Sutanto I, Tjahjono B, Basri H, Taylor WR, Putri FA, Meilia RA, Setiabudy R, Nurleila S, Ekawati LL, Elyazar I, Farrar J, Sudoyo H, Baird JK.

Antimicrob Agents Chemother. 2013 Mar;57(3):1128-35. doi: 10.1128/AAC.01879-12. Epub 2012 Dec 17.

PMID: 23254437Free PMC ArticleSimilar articlesSelect item 2386376950.

Surveillance for travel-related disease--GeoSentinel Surveillance System, United States, 1997-2011.

Harvey K, Esposito DH, Han P, Kozarsky P, Freedman DO, Plier DA, Sotir MJ; Centers for Disease Control and Prevention (CDC).

MMWR Surveill Summ. 2013 Jul 19;62:1-23.

PMID: 23863769Free ArticleSimilar articlesSelect item 2664311651.

Improving the radical cure of vivax malaria (IMPROV): a study protocol for a multicentre randomised, placebo-controlled comparison of short and long course primaquine regimens.

IMPROV Study Group.

BMC Infect Dis. 2015 Dec 7;15:558. doi: 10.1186/s12879-015-1276-2.

PMID: 26643116Free PMC ArticleSimilar articlesSelect item 1287525252.

Malaria surveillance--United States, 2001.

Filler S, Causer LM, Newman RD, Barber AM, Roberts JM, MacArthur J, Parise ME, Steketee RW; Centers for Disease Control and Prevention (CDC).

MMWR Surveill Summ. 2003 Jul 18;52(5):1-14.

PMID: 12875252Free ArticleSimilar articlesSelect item 2688807553.

Tafenoquine treatment of Plasmodium vivax malaria: suggestive evidence that CYP2D6 reduced metabolism is not associated with relapse in the Phase 2b DETECTIVE trial.

St Jean PL, Xue Z, Carter N, Koh GC, Duparc S, Taylor M, Beaumont C, Llanos-Cuentas A, Rueangweerayut R, Krudsood S, Green JA, Rubio JP.

Malar J. 2016 Feb 18;15:97. doi: 10.1186/s12936-016-1145-5.

PMID: 26888075Free PMC ArticleSimilar articlesSelect item 1672397154.

Malaria surveillance--United States, 2004.

Skarbinski J, James EM, Causer LM, Barber AM, Mali S, Nguyen-Dinh P, Roberts JM, Parise ME, Slutsker L, Newman RD.

MMWR Surveill Summ. 2006 May 26;55(4):23-37.

PMID: 16723971Free ArticleSimilar articlesSelect item 2057715855.

Malaria surveillance - United States, 2008.

Mali S, Steele S, Slutsker L, Arguin PM; Centers for Disease Control and Prevention (CDC).

MMWR Surveill Summ. 2010 Jun 25;59(7):1-15. Erratum in: MMWR Surveill Summ. 2010 Jul 30;59(29):914.

PMID: 20577158Free ArticleSimilar articlesSelect item 1262515056.

Comparison of tafenoquine (WR238605) and primaquine in the post-exposure (terminal) prophylaxis of vivax malaria in Australian Defence Force personnel.

Nasveld P, Kitchener S, Edstein M, Rieckmann K.

Trans R Soc Trop Med Hyg. 2002 Nov-Dec;96(6):683-4.

PMID: 12625150Similar articlesSelect item 1593115457.

Malaria surveillance--United States, 2003.

Eliades MJ, Shah S, Nguyen-Dinh P, Newman RD, Barber AM, Nguyen-Dinh P, Roberts JM, Mali S, Parise ME, Barber AM, Steketee R.

MMWR Surveill Summ. 2005 Jun 3;54(2):25-40.

PMID: 15931154Free ArticleSimilar articlesSelect item 3026931258.

Comparative ophthalmic assessment of patients receiving tafenoquine or chloroquine/primaquine in a randomized clinical trial for Plasmodium vivax malaria radical cure.

Warrasak S, Euswas A, Fukuda MM, Ittiverakul M, Miller RS, Krudsood S, Ohrt C.

Int Ophthalmol. 2018 Sep 29. doi: 10.1007/s10792-018-1003-2. [Epub ahead of print]

PMID: 30269312Similar articlesSelect item 2661084459.

Summary of anti-malarial prophylactic efficacy of tafenoquine from three placebo-controlled studies of residents of malaria-endemic countries.

Dow GS, Liu J, Lin G, Hetzell B, Thieling S, McCarthy WF, Tang D, Smith B.

Malar J. 2015 Nov 26;14:473. doi: 10.1186/s12936-015-0991-x.

PMID: 26610844Free PMC ArticleSimilar articlesSelect item 1622536660.

Modern malaria chemoprophylaxis.

Shanks GD, Edstein MD.

Drugs. 2005;65(15):2091-110. Review.

PMID: 16225366

Malaria surveillance--United States, 2011.

Cullen KA, Arguin PM; Division of Parasitic Diseases and Malaria, Center for Global Health, Centers for Disease Control and Prevention (CDC).

MMWR Surveill Summ. 2013 Nov 1;62(5):1-17.

PMID: 24172939Free ArticleSimilar articlesSelect item 2214443762.

Review: Malaria chemoprophylaxis for travelers to Latin America.

Steinhardt LC, Magill AJ, Arguin PM.

Am J Trop Med Hyg. 2011 Dec;85(6):1015-24. doi: 10.4269/ajtmh.2011.11-0464. Review.

PMID: 22144437Free PMC ArticleSimilar articlesSelect item 151875263.

Prophylaxis for malaria. Helping world travelers come home healthy.

Amin NM.

Postgrad Med. 1992 Sep 1;92(3):161-8. Review.

PMID: 1518752Similar articlesSelect item 1117773364.

Recent Advances in the Prophylaxis and Treatment of Malaria.

Labb AC, Loutfy MR, Kain KC.

Curr Infect Dis Rep. 2001 Feb;3(1):68-76.

PMID: 11177733Similar articlesSelect item 1058580365.

Primaquine as prophylaxis for malaria for nonimmune travelers: A comparison with mefloquine and doxycycline.

Schwartz E, Regev-Yochay G.

Clin Infect Dis. 1999 Dec;29(6):1502-6.

PMID: 10585803Similar articlesSelect item 1868273966.

A randomised trial of an eight-week, o­nce weekly primaquine regimen to prevent relapse of plasmodium vivax in Northwest Frontier Province, Pakistan.

Leslie T, Mayan I, Mohammed N, Erasmus P, Kolaczinski J, Whitty CJ, Rowland M.

PLoS o­ne. 2008 Aug 6;3(8):e2861. doi: 10.1371/journal.pone.0002861.

PMID:18682739Free PMC ArticleSimilar articlesSelect item 1512398367.

Malaria surveillance--United States, 2002.

Shah S, Filler S, Causer LM, Rowe AK, Bloland PB, Barber AM, Roberts JM, Desai MR, Parise ME, Steketee RW.

MMWR Surveill Summ. 2004 Apr 30;53(1):21-34.

PMID: 15123983Free ArticleSimilar articlesSelect item 1468934968.

Primaquine for prevention of malaria in travelers.

Baird JK, Fryauff DJ, Hoffman SL.

Clin Infect Dis. 2003 Dec 15;37(12):1659-67. Epub 2003 Nov 20.

PMID: 14689349Similar articlesSelect item 1856656869.

Malaria surveillance--United States, 2006.

Mali S, Steele S, Slutsker L, Arguin PM; Centers for Disease Control and Prevention (CDC).

MMWR Surveill Summ. 2008 Jun 20;57(5):24-39.

PMID: 18566568Free ArticleSimilar articlesSelect item 2650035170.

Estimation of the Antirelapse Efficacy of Tafenoquine, Using Plasmodium vivax Genotyping.

Beck HP, Wampfler R, Carter N, Koh G, Osorio L, Rueangweerayut R, Krudsood S, Lacerda MV, Llanos-Cuentas A, Duparc S, Rubio JP, Green JA.

J Infect Dis. 2016 Mar 1;213(5):794-9. doi: 10.1093/infdis/jiv508.Epub 2015 Oct 23.

PMID: 26500351Free PMC ArticleSimilar articlesSelect item 1555025471.

Treatment of acute vivax malaria with tafenoquine.

Nasveld P, Kitchener S.

Trans R Soc Trop Med Hyg. 2005 Jan;99(1):2-5.

PMID: 15550254Similar articlesSelect item 1173687772.

Population pharmacokinetics of the new antimalarial agent tafenoquine in Thai soldiers.

Edstein MD, Kocisko DA, Brewer TG, Walsh DS, Eamsila C, Charles BG.

Br J Clin Pharmacol. 2001 Dec;52(6):663-70.

PMID: 11736877Free PMC ArticleSimilar articlesSelect item 1456179373.

Delayed o­nset of malaria--implications for chemoprophylaxis in travelers.

Schwartz E, Parise M, Kozarsky P, Cetron M.

N Engl J Med. 2003 Oct 16;349(16):1510-6.

PMID: 14561793Free ArticleSimilar articlesSelect item 1751785074.

Population pharmacokinetics of tafenoquine during malaria prophylaxis in healthy subjects.

Charles BG, Miller AK, Nasveld PE, Reid MG, Harris IE, Edstein MD.

Antimicrob Agents Chemother. 2007 Aug;51(8):2709-15. Epub 2007 May 21.

PMID: 17517850Free PMC ArticleSimilar articlesSelect item 3020182075.

Population Pharmacokinetics of Tafenoquine, a Novel Antimalarial.

Thakkar N, Green JA, Koh GCKW, Duparc S, Tenero D, Goyal N.

Antimicrob Agents Chemother. 2018 Oct 24;62(11). pii: e00711-18. doi: 10.1128/AAC.00711-18. Print 2018 Nov.

PMID: 30201820Free PMC ArticleSimilar articlesSelect item 1170057776.

A new primaquine analogue, tafenoquine (WR 238605), for prophylaxis against Plasmodium falciparum malaria.

Shanks GD, Oloo AJ, Aleman GM, Ohrt C, Klotz FW, Braitman D, Horton J, Brueckner R.

Clin Infect Dis. 2001 Dec 15;33(12):1968-74. Epub 2001 Nov 7.

PMID: 11700577Similar articlesSelect item 2650575377.

Strategies for understanding and reducing the Plasmodium vivax and Plasmodium ovale hypnozoite reservoir in Papua New Guinean children: a randomised placebo-controlled trial and mathematical model.

Robinson LJ, Wampfler R, Betuela I, Karl S, White MT, Li Wai Suen CS, Hofmann NE, Kinboro B, Waltmann A, Brewster J, Lorry L, Tarongka N, Samol L, Silkey M, Bassat Q, Siba PM, Schofield L, Felger I, Mueller I.

PLoS Med. 2015 Oct 27;12(10):e1001891. doi: 10.1371/journal.pmed.1001891. eCollection 2015 Oct.

PMID: 26505753Free PMC ArticleSimilar articlesSelect item 1751941578.

Controversies and misconceptions in malaria chemoprophylaxis for travelers.

Chen LH, Wilson ME, Schlagenhauf P.

JAMA. 2007 May 23;297(20):2251-63. Review.

PMID: 17519415Similar articlesSelect item 2398459579.

[Plasmodium malariae malaria with more than a 4-month incubation period: difficult to distinguish from a relapse of Plasmodium vivax malaria].

Hase R, Uwamino Y, Muranaka K, Tochitani K, Sogi M, Kitazono H, Hosokawa N.

Kansenshogaku Zasshi. 2013 Jul;87(4):446-50. Japanese.

PMID: 23984595Similar articlesSelect item 1177090680.

Malaria surveillance--United States, 1998.

Holtz TH, Kachur SP, MacArthur JR, Roberts JM, Barber AM, Steketee RW, Parise ME.

MMWR CDC Surveill Summ. 2001 Dec 7;50(5):1-20.

PMID: 11770906Free ArticleSimilar articlesOrigins and implications of neglect of G6PD deficiency and primaquine toxicity in Plasmodium vivax malaria.

Baird K.Pathog Glob Health. 2015 May;109(3):93-106. doi: 10.1179/2047773215Y.0000000016. Review.PMID: 25943156Free PMC ArticleSimilar articlesSelect item 2501612082.

[Two imported and relapsed of Plasmodium vivax malaria cases and primaquine prophylaxis].

Hatipo?lu M, Ulay A, Turhan V, Karagz E, Erdem H, Acar A, o­ncl O, Grenek L.Turkiye Parazitol Derg. 2014 Jun;38(2):120-3. doi: 10.5152/tpd.2014.3159. Turkish. PMID: 25016120Free ArticleSimilar articlesSelect item 981535183.

Arguments against Chemoprophylaxis in Areas at Low Risk for Chloroquine-Resistant Plasmodium falciparum.

Armengaud M.J Travel Med. 1995 Mar 1;2(1):4-5.PMID: 9815351Free ArticleSimilar articlesSelect item 2319949084.

Chemotherapeutic strategies for reducing transmission of Plasmodium vivax malaria.

Douglas NM, John GK, von Seidlein L, Anstey NM, Price RN.Adv Parasitol. 2012;80:271-300. doi: 10.1016/B978-0-12-397900-1.00005-0. Review.PMID: 23199490Similar articlesSelect item 1710743185.

Tertian malaria (Plasmodium vivax and Plasmodium ovale) in two travelers despite atovaquone-proguanil prophylaxis.

Jimnez BC, Navarro M, Huerga H, Lpez-Romn E, Mendoza A, Lpez-Vlez R.J Travel Med. 2006 Nov-Dec;13(6):373-5.PMID: 17107431Free ArticleSimilar articlesSelect item 1429600486.

Latent infections with Plasmodium ovale malaria.

MILLER MJ, MARCUS DM, CAMERON DG.Can Med Assoc J. 1965 Jun 12;92:1241-7.PMID: 14296004Free PMC ArticleSimilar articlesSelect item 1259463387.

A randomized, double-blind, placebo-controlled, dose-ranging trial of tafenoquine for weekly prophylaxis against Plasmodium falciparum.

Hale BR, Owusu-Agyei S, Fryauff DJ, Koram KA, Adjuik M, Oduro AR, Prescott WR, Baird JK, Nkrumah F, Ritchie TL, Franke ED, Binka FN, Horton J, Hoffman SL.Clin Infect Dis. 2003 Mar 1;36(5):541-9. Epub 2003 Feb 14.PMID: 12594633Similar articlesSelect item 1683771988.

Imported non-Plasmodium falciparum malaria: a five-year prospective study in a European referral center.

Bottieau E, Clerinx J, Van Den Enden E, Van Esbroeck M, Colebunders R, Van Gompel A, Van Den Ende J.Am J Trop Med Hyg. 2006 Jul;75(1):133-8.PMID: 16837719Similar articlesSelect item 1681482389.

Gender differences in gastrointestinal disturbances and plasma concentrations of tafenoquine in healthy volunteers after tafenoquine administration for post-exposure vivax malaria prophylaxis.

Edstein MD, Nasveld PE, Kocisko DA, Kitchener SJ, Gatton ML, Rieckmann KH.Trans R Soc Trop Med Hyg. 2007 Mar;101(3):226-30. Epub 2006 Jun 30.PMID: 16814823Similar articlesSelect item 2845018590.

Prophylactic efficacy of primaquine for preventing Plasmodium falciparum and Plasmodium vivax parasitaemia in travelers: A meta-analysis and systematic review.

Kolifarhood G, Raeisi A, Ranjbar M, Haghdoust AA, Schapira A, Hashemi S, Masoumi-Asl H, Mozafar Saadati H, Azimi S, Khosravi N, Kondrashin A.Travel Med Infect Dis. 2017 May - Jun;17:5-18. doi: 10.1016/j.tmaid.2017.04.005. Epub 2017 Apr 24. Review.PMID: 28450185Similar articlesSelect item 1242090591.

Malaria surveillance--United States, 1999.

Newman RD, Barber AM, Roberts J, Holtz T, Steketee RW, Parise ME.MMWR Surveill Summ. 2002 Mar 29;51(1):15-28.PMID: 12420905Free ArticleSimilar articlesSelect item 1625604792.

Risk and spectrum of diseases in travelers to popular tourist destinations.

Rack J, Wichmann O, Kamara B, Gnther M, Cramer J, Schnfeld C, Henning T, Schwarz U, Mhlen M, Weitzel T, Friedrich-Jnicke B, Foroutan B, Jelinek T.J Travel Med. 2005 Sep-Oct;12(5):248-53.PMID: 16256047Free ArticleSimilar articlesSelect item 2624836293.

Exposure-Response Analyses for Tafenoquine after Administration to Patients with Plasmodium vivax Malaria.

Tenero D, Green JA, Goyal N.Antimicrob Agents Chemother. 2015 Oct;59(10):6188-94. doi: 10.1128/AAC.00718-15. Epub 2015 Jul 27.PMID: 26248362Free PMC ArticleSimilar articlesSelect item 2693089094.

Primaquine treatment for Plasmodium vivax-an essential tool for malaria control and elimination in Papua New Guinea.

Betuela I, Robinson LJ, Hetzel MW, Laman M, Siba PM, Bassat Q, Mueller I.P N G Med J. 2014 Mar-Dec;57(1-4):68-74.PMID: 26930890Similar articlesSelect item 1848606795.

Failure of atovaquone/proguanil to prevent Plasmodium ovale malaria in traveler returning from Cameroon.

Gallien S, Taieb F, Schlemmer F, Lagrange-Xelot M, Atlan A, Sarfati C, Molina JM.Travel Med Infect Dis. 2008 May;6(3):128-9. doi: 10.1016/j.tmaid.2008.01.011. Epub 2008 Apr 2.PMID: 18486067

(Collected by Dr. Huynh Hong Quang)  
    Other news »


Documentary form
Research studies
Malaria forecast & management
Document management
Personel management
Official document
Malaria facts
Malaria epidemic
Petechial fever
Hospital & medical centre
Your doctor

Institue of Malariology Parastology and Entomology Quy Nhon
Address: 611B Nguyen Thai Hoc Str,. Quy Nhon City
Tel: (84) 056 846571 Fax: (84) 056 846755
• Designed by Quang Ich JSC